Opinion
2012-1280
04-30-2012
IN RE CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION EURAND, INC. (NOW KNOWN AS APTALIS PHARMATECH, INC.), CEPHALON, INC., AND ANESTAAG, Plaintiffs- Appellees, v. IMPAX LABORATORIES, INC., Defendant-Appellant, AND MYLAN INC., MYLAN PHARMACEUTICALS INC., PAR PHARMACEUTICAL INC., and TWI PHARMACEUTICALS INC., Defendants.
NOTE: This order is nonprecedential.
Appeal from the United States District Court for the District of Delaware in case no. 09-MD-2118, Judge Sue L. Robinson.
ON MOTION
Before RADER, Chief Judge.
ORDER
Impax Laboratories, Inc. moves to expedite the briefing schedule. Eurand, Inc. et al. oppose.
Impax may of course significantly self-expedite the case by filing its own briefs early. Impax has not shown that the time for the appellees to file their briefs should be shortened. The appellees should not anticipate any extensions of time to file their briefs. The case will be placed on the next available oral argument calendar after the briefing is completed, which is the usual course, and thus no motion is necessary to obtain that relief.
Accordingly,
IT IS ORDERED THAT:
Impax's motion to expedite is denied.
FOR THE COURT
_________________
Jan Horbaly
Clerk
cc: Debra J. McComas, Esq.
John R. Lane, Esq.
James W. Wallace, Jr., Esq.
sl9